Primary Ciliary Dyskinesia — Research Summary
Printed from RareWays (rareways.com.au) on 26 July 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Ultra-low contrast agent dosage in photon-counting CT angiography of the thoracoabdominal aorta.
Hennes Jan-Lucca et al. — European journal of radiology open (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42383172/
- 2.
Traditional Chinese medicine treatment of asthma: From the insight on programmed cell death.
Yao Dengxiang et al. — Journal of ethnopharmacology (15 November 2026)
https://pubmed.ncbi.nlm.nih.gov/42314809/
- 3.
Janus TiO
Cheng Ziyi et al. — Biomaterials (1 November 2026)
https://pubmed.ncbi.nlm.nih.gov/42176394/
- 4.
A porous phosphate-rich β-cyclodextrin polymer for efficient and broad-spectrum enrichment of antibiotics.
Peng Sheng et al. — Analytica chimica acta (8 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42242818/
- 5.
The nuclear lamina protein NEMP1 regulates tapetal programmed cell death and pollen development in rice.
Tariq Naveed et al. — aBIOTECH (1 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42211884/
Clinical Trials — Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects
Completed — Phase 1 — ReCode Therapeutics
https://clinicaltrials.gov/study/NCT05737485
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Primary Ciliary Dyskinesia
Primary ciliary dyskinesia is a rare genetic condition caused by defective cilia function, leading to chronic respiratory infections, bronchiectasis, and fertility problems. Kartagener syndrome (with situs inversus) is a subset. It is significantly underdiagnosed. No disease-modifying therapies currently exist, but several are in trials.
Most Recent Research
PURPOSE: To assess the viability of an ultra-low contrast agent protocol (ULC) for aortic photon-counting CT angiography (PCD-CTA). MATERIALS AND METHODS: For this retrospective, single-center study, 31 consecutive patients receiving PCD-CTA with 48 ml Imeron® 150mgI/ml (≙ 7.2 g iodine) were assessed. Virtual monoenergetic images with 45/55 keV were compared to a control sample scanned with radiation-dose-equivalent 55 keV protocols (120kVp; image-quality-level 42) employing standard (SC; 60 ml Imeron® 350mgI/ml ≙ 21 g iodine) and low contrast agent dose (LC; 40 ml Imeron® 350 mg/ml ≙ 14 g iodine). Luminal attenuation and image noise were measured, while contrast-to-noise ratios were calculated. Five radiologists rated overall image quality, luminal attenuation, and diagnostic confidence using a 5-point rating scale. RESULTS: Radiation dose and body-mass-index did not differ significantly among groups (p > .999, each). ULC scans displayed significantly lower CNR (55 keV: 12.2 ± 2.7; 45 keV: 20.0 ± 4.6) than SC (35.3 ± 7.5) and LC studies (27.4 ± 10.7; each p ≤ .001) due to reduced luminal attenuation (ULC-55keV: 211.9 ± 27.3HU; ULC-45keV: 302.9 ± 42.8HU; SC 504.3 ± 70.9HU; LC: 380.8 ± 98.3HU; p < .001). Overall image quality of protocols was rated similar (each 4 [4-4]; p ≥ .395), while luminal attenuation of ULC-45keV (4 [4-4]) was rated inferior to SC (5 [5-5]; p < 0.001) but not to LC (4 [4-5]; p = 0.25). Diagnostic confidence was good for ULC (45 keV: 4 [4-4]); 55 keV: 3 [3-4]) and excellent for SC (5 [5-5]) and LC (5 [4-5]). CONCLUSION: Despite inferior contrast, aortic PCD-CTA with ultra-low contrast agent dosage at 45 keV allows for diagnostic image quality. The proposed scan protocol may hold potential for kidney protection in vulnerable patient groups.
Common Questions
What is Primary Ciliary Dyskinesia?
Primary ciliary dyskinesia is a rare genetic condition caused by defective cilia function, leading to chronic respiratory infections, bronchiectasis, and fertility problems. Kartagener syndrome (with situs inversus) is a subset. It is significantly underdiagnosed. No disease-modifying therapies currently exist, but several are in trials.
How many clinical trials are available for Primary Ciliary Dyskinesia?
RareWays currently indexes 60 clinical trials for Primary Ciliary Dyskinesia, of which 15 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Primary Ciliary Dyskinesia come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Primary Ciliary Dyskinesia.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.